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Occult hepatitis B virus (HBV) infection has been reported among patients with hepatitis C virus (HCV) infection and
hepatocellular carcinoma (HCC). Our aim was to evaluate the presence of occult HBV infection in patients with HCV-related liver
cirrhosis (LC) with or without HCC in São Paulo, Brazil. Serum and liver tissue samples from 50 hepatitis B surface antigen-
negative patients with HCV-related LC who underwent liver transplantation at the University of São Paulo School of Medicine
Hospital from 1993 to 2004 were divided into groups with LC only (N = 33) and with LC plus HCC (N = 17). HBV DNA was assayed
for serum and paraffin-embedded liver tissue (tumoral and non-tumoral) using real time PCR and only 1 case with HCC had HBV
DNA-positive serum. All liver samples were negative. HCV genotype 3 was detected in 17/39 (43.7%) cases. In conclusion, using
a sensitive real time PCR directed to detect HBV variants circulating in Brazil, occult hepatitis B infection was not found among
HCV-positive cirrhotic patients and was rarely found among HCV-positive HCC patients. These results are probably related to
the low prevalence of HBV infection in our population. Furthermore, we have also shown that HCV genotype 3 is frequently found
in Brazilian cirrhotic patients, particularly when they also have HCC. More studies involving a large number of cases should be
carried out to confirm these data and to further characterize Brazilian HCV genotype isolates to elucidate genetic features that
might be related to its carcinogenic potential.
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Introduction
Hepatitis B virus (HBV) infection is generally deter-
mined by the detection of viral specific antigens and anti-
bodies (hepatitis B surface antigen, HBsAg; hepatitis B e
antigen, HBeAg; anti-hepatitis B core antigen, anti-HBc),
and viral DNA (HBV DNA) in serum. In some patients that
do not have detectable HBsAg in serum, HBV DNA can be
detected in serum or liver samples and their condition is
defined as occult or cryptic hepatitis B. Occult HBV infec-
tion has been found among patients with hepatitis C, HIV
infection, hepatitis non-A-E, and hepatocellular carcinoma
(HCC) (1).
Several mechanisms have been considered for occult
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infections by HBV such as low HBV DNA and HBsAg levels
(2), mutations in HBV DNA sequence (3), viral DNA inte-
gration in the host genome (4), infection of peripheral blood
mononuclear cells (5), production of immune complexes
containing HBV (6), altered host immune response (7),
and interference of other viruses (mainly hepatitis C virus,
HCV) (8-15).
Occult HBV infection has been demonstrated in chronic
hepatitis patients infected with HCV, being associated with
a moderate intra-hepatocyte HBV DNA level (9) and a low
frequency of infected cells (10). These results suggest that
occult HBV infection may interfere with the clinical picture
of chronic HCV infection, accelerating its evolution to cir-
rhosis (11). Evidence for previous HBV infection even in
the absence of HBV DNA detection has been related to the
severity of the disease in anti-HCV-positive chronic hepa-
titis patients (12) but these results were not confirmed by
other investigators (13-15).
Occult HBV has been associated with more advanced
fibrosis/cirrhosis and with a poor response to interferon (8),
but not in all studies. Cirrhosis is considered to be the most
important risk factor for HCC. Therefore, besides having a
possible direct oncogenetic effect, occult HBV infection
may increase neoplastic transformation in HCV-infected
patients (4,8). The oncogenicity of occult HBV infection is
related to the transactivating role of the HBx protein and to
the ability of HBV to integrate the host genome (16,17).
Indeed, some studies have shown that HBV DNA could be
detected in HBsAg-negative patients with HCC (18,19).
The frequency of diagnosis depends on the relative
sensitivity of both HBsAg and HBV DNA assays as well as
on the prevalence of HBV infection in the population (20).
In Brazil, HBV prevalence is variable, since this is a large
country with high cultural, ethnic and social diversity. Most
Brazilian regions show intermediate endemicity ranging
from 1 to 2% in studies with healthy populations and blood
donors. The Southwest region of Paraná State and some
indigenous populations of the Amazon Basin (North re-
gion) show HBsAg rates around 8% (high endemicity) (21).
HBV seroprevalence is higher among males than females
and HBV is two times more frequent in low socio-economic
level populations (21).
Few studies have addressed the presence of occult
HBV infection in Brazil. In Rio de Janeiro, it was found in 16
(13.9%) of 115 HBsAg-negative, anti-HIV- and anti-HBc-
positive patients (22), while in Campinas, it was found in
4% of blood donors, 3.4% of HIV-co-infected patients and
in 24.0% of anti-HCV-positive patients (23). On the other
hand, another study did not find any HBV DNA-positive
case among 105 hepatitis C and non-A-E patients followed
in São Paulo (24).
The aim of the present study was to determine the
occurrence of occult HBV infection in cirrhotic HCV pa-
tients with or without concomitant HCC and the distribution
of HCV genotypes among these cases.
Patients and Methods
Patients
We analyzed serum and liver explant samples from 50
HCV-infected cirrhotic patients with or without HCC, sub-
mitted to liver transplantation. Patients were divided into
two groups: group 1, HCV-infected patients with liver cir-
rhosis (N = 33), and group 2, HCV-infected patients with
liver cirrhosis and HCC (N = 17).
Serum samples were collected just before liver trans-
plantation at the Hospital das Clínicas, University of São
Paulo School of Medicine, during the period from 1993 to
2004 and were stored at -20°C.
Liver explants
Liver explants were analyzed by a specialized patholo-
gist. Macroscopic examination was carefully carried out to
determine the extent and morphology of liver lesions. The
number and size of nodules were recorded. Sections of
non-tumoral and tumoral liver tissues were stored in for-
maldehyde for histopathological analysis of the lesions
and for further analysis of HBV DNA by PCR. All paraffin-
embedded tissue samples were analyzed according to the
Edmondson and Steiner Classification (25) to evaluate the
grade of HCC differentiation.
Clinical data
The clinical data of all 50 patients were retrospectively
reviewed in order to collect information about previous
laboratory tests (aspartate aminotransferase; alanine ami-
notransferase; γ-glutamyl transpeptidase; alkaline phos-
phatase; total bilirubin, albumin, creatinine, α-fetoprotein,
prothrombin time expressed as international normalized
ratio) and clinical (ascites and hepatic encephalopathy)
and demographic (gender and age) data. Patients were
classified according to MELD scores (26) and to the Child-
Turcot Classification modified by Pugh (27).
Serological tests
All patients in this study were tested and found to be
anti-HCV seropositive and HBsAg seronegative. Serologi-
cal markers for HBV (HBsAg, anti-HBc, and anti-HBs) and
HCV (anti-HCV) infection were confirmed in stored serum
samples from all patients. All serological markers were
determined by immunoenzymatic assays (ELISA, Abbott
Laboratories, North Chicago, IL, USA).
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Hepatitis C virus detection and genotyping
Viral RNA was extracted from 100-µL serum samples
using the guanidine isothiocyanate-phenol-chloroform
method, as previously described (28). The 5' untranslated
region of the HCV genome was amplified and positive
samples were determined by agarose gel electrophoresis.
PCR products were submitted to cycle sequencing
reactions using dideoxynucleotides with fluorescent mark-
ers (ABI Prism® BigDye™ Terminator Cycle Sequencing
Ready Reaction Kit, Applied Biosystems, Foster City, CA,
USA). Genotyping was carried out by aligning both se-
quenced strands (sense and antisense) and the resulting
consensus sequence was compared with a database
(29).
Hepatitis B virus detection
HBV DNA was extracted from 200-µL serum samples
using the QIAamp DNA mini-kit (Qiagen, Hilden, Ger-
many) and eluted in 50 µL. Paraffin-embedded liver tissue
was cut into 10-µm sections and the slides were cleared
with xylene. DNA was then extracted using the same kit as
for the serum samples and its quality was tested by PCR
amplification of the ß actin gene as described by Dakhama
et al. (30).
HBV DNA was detected by a real time PCR (RT-PCR)
assay developed by us. Primers and the TaqMan probe for
amplification and detection of the S gene region of HBV were
chosen using the Primer Express program (Applied Biosys-
tems) based on 62 HBV sequences from a previous paper
describing HBV genotypes among Brazilian patients (31).
Primers and probe sequences utilized were HBV362F 5' -
CCT GGY TAT CGY TGG ATG TGT - 3'; HBV477R 5' - GGA
CAV ACG KGC AAC ATA CCT T - 3'; HBV419T 5' - FAM -
CTA TGC CTC ATC TTC TT - 3' - MGB. In the present assay,
we used a 50-µL mix containing 1X TaqMan Universal PCR
Master Mix, 20 µM of each primer and a TaqMan probe (FAM
probe), 1X IPC Mix (VIC probe), 1X IPC DNA and 5 µL of
extracted sample. All reagents and kits were from Applied
Biosystems. Absolute quantification of HBV DNA was car-
ried out with an ABI PRISM 7500 real time analyzer using
universal cycling conditions. The detection limit for RT-PCR
was 50 IU/mL. This method was validated by comparison
with results obtained from Quest Diagnostics (Sonora, CA,
USA) and from a nested HBV DNA PCR protocol carried out
by our group (32).
Statistical analysis
Statistical analysis was performed with the SPSS Soft-
ware, version 12. Data were analyzed by the chi-square
test, likelihood ratio, Fisher exact test, Student t-test, and
Mann-Whitney test, when needed (33).
Table 1. Biochemical and coagulation data for HCV-infected
patients with liver cirrhosis with and without hepatocellular carci-
noma (HCC).
Variable Without HCC With HCC
(N = 33) (N = 17)
AST (U/L) 71.9 ± 40.6 80.0 ± 67.2
ALT (U/L) 64.2 ± 40.7 72.1 ± 61.8
GGT (U/L) 157.9 ± 192.1 86.7 ± 96.9
APh (U/L) 177.2 ± 162.6 140.8 ± 63.0
Total bilirubin (mg/dL) 2.6 ± 1.6 2.2 ± 1.5
Albumin (g/dL) 3.0 ± 0.6 3.4 ± 0.7
Creatinin (mg/dL) 1.2 ± 0.8 1.1 ± 0.3
α-fetoprotein (ng/mL) 23.0 ± 47.1 106.5 ± 328.7
INR 1.5 ± 0.4 1.4 ± 0.4
AST = aspartate aminotransferase; ALT = alanine aminotrans-
ferase; GGT = γ-glutamyl transpeptidase; APh = alkaline phos-
phatase; INR = prothrombin time expressed as international
normalized ratio. There was no statistically significant difference
between groups (Mann-Whitney test).
Results
Demographic and clinical data
Group 1 consisted of 21 men and 12 women with a
median age of 53.7 ± 8.6 years, and group 2 consisted of
13 men and 4 women with a median age of 59.5 ± 5.7 years
(P = 0.3770 and 0.0029, respectively).
Child-Turcot classification modified by Pugh was: group
1 = child A: 0, B: 17, and C: 16 patients; group 2 = child A:
4, B: 7, and C: 6 patients (P = 0.0090), and MELD score
was: group 1 = 13.80 ± 5.03; group 2 = 12.5 ± 6.33 (P =
0.3730).
Initial forms of HCC cell differentiation were more fre-
quent, according to the Edmondson and Steiner (25) Clas-
sification: grade I = 2 (11.7%), grade II = 11 (64.7%), and
grade III = 4 (23.5%). Nodules of less than 3.0 cm (15;
88.2%) were also more frequent than nodules of 3.0-5.0
cm (2; 11.7%).
Laboratory results
Table 1 summarizes the biochemical and coagulation
results for both groups of patients. None of the variables
showed statistically significant differences between the
two groups.
Since the standard deviation was very high for α-
fetoprotein, its results were stratified into grades: I = 0-9
ng/mL, II = 10-99 ng/mL, and III = ≥100 ng/mL (Table 2).
Stratified data analysis did not show a statistically signifi-
cant difference (P = 0.49).
Results of the serological HBV markers are shown in
Table 3.
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HCV RNA was detected and genotyped in 39 serum
samples. Due to samples storage at -20°C, in some of
them it was not possible to extract viral RNA for genotyp-
ing, as shown in Table 4. In group 1 there was a predomi-
nance of genotype 1 HCV infection (60.0%) while in group
2 genotype non-1 HCV was more frequent (9/15, 60.0%),
mainly genotype 3. These differences were not statistically
significant.
HBV DNA detection in serum and in tumoral and non-
tumoral liver tissues was carried out by RT-PCR. Results
are shown in Table 5. In two liver tissue samples it was not
possible to amplify the internal control DNA (ß actin) due to
PCR inhibition and therefore they could not be used to
evaluate the presence of HBV DNA.
There was only one positive sample in the serum from
a 66-year-old male patient with isolated total anti-HBc and
HCC and with two grade II hepatic neoplastic nodules
according to the Edmondson and Steiner classification
and HCV genotype 1.
Discussion
The frequency of occult HBV infection was very low in
the cirrhotic Brazilian patients followed up in São Paulo
with or without HCC studied here, since only one serum
sample and none of the liver tissues were HBV DNA
positive. The prevalence of occult infection seems to be
closely related to the prevalence of HBV infection in differ-
ent parts of the world. Several investigators have shown an
intermediate to high occurrence of HBV occult infection,
both in serum and in liver tissue (1,2,4,8-15). In Brazil,
particularly in the Southeast region, the prevalence of HBV
infection is very low (21) and this may have contributed to
our results of an HBV occult infection rate close to zero. A
recent study involving Chinese patients reported a high
rate (10/19) of false-positive HBV DNA by PCR in patients
with hepatitis B core antibody (anti-HBc) alone. Thus, a
highly sensitive and specific HBV PCR amplification assay
is essential to determine the prevalence of occult HBV
infection (34).
It is noteworthy that we only detected HBV DNA in one
serum sample and in none of the liver samples. This
finding is probably related to the fact that the small liver
biopsy fragment analyzed by us did not contain viral par-
ticles that might be found in other liver fragments. Another
possible explanation is that we analyzed only paraffin-
embedded fragments and perhaps a higher sensitivity
could have been achieved if we had analyzed fresh liver
fragments immediately transferred to a DNA-conserving
storage solution. To decrease the impact of false-negative
results due to inhibition of amplification, HBV DNA amplifi-
Table 2. Stratification of the α-fetoprotein results for HCV-in-
fected patients with liver cirrhosis with and without hepatocellular
carcinoma (HCC).
α-fetoprotein (ng/mL) Without HCC With HCC
(N = 33)  (N = 17)
0-9 23/33 (69.7%) 9/17 (52.9%)
10-99 8/33 (24.2%) 6/17 (35.3%)
≥100 2/33 (6%) 2/17 (11.7%)
There was no statistically significant difference between groups
(Mann-Whitney test).
Table 3. Serological hepatitis B virus (HBV) markers of HCV-
infected patients with liver cirrhosis with and without hepatocellu-
lar carcinoma (HCC).
Without HCC With HCC
(N = 33) (N = 17)
Total anti-HBc (isolated) 4/33 (12.1%) 3/17 (17.6%)
Total anti-HBc and anti-HBs 3/33 (9.0%) 2/17 (11.7%)
No HBV markers 22/33 (66.7%) 11/17 (64.0%)
Anti-HBs (isolated) 4/33 (12.1%) 1/17 (5.8%)
Anti-HBc = anti-hepatitis B core antigen; anti-HBs = anti-hepati-
tis B surface antigen. There was no statistically significant differ-
ence between groups (Yates corrected chi-square or Fisher
exact tests).
Table 4. Hepatitis C virus (HCV) genotypes found in HCV-in-
fected patients with liver cirrhosis with and without hepatocellular
carcinoma (HCC).
HCV Without HCC With HCC Total
genotype (N = 24) (N = 15)
1 15/24 (60.0%) 6/15 (40.0%) 21/39 (53.7%)
2 0 1/15 (6.7%) 1/39 (2.6%)
3 9/24 (40.0%) 8/15 (53.3%) 17/39 (43.7%)
There was no statistically significant difference between groups
(Yates corrected chi-square or Fisher exact tests).
Table 5. Hepatitis B virus DNA (HBV DNA) detection in serum
and liver tissue by real time PCR in HCV-infected patients with
liver cirrhosis with and without hepatocellular carcinoma (HCC).
HBV DNA Without HCC With HCC
(N = 33) (N = 17)
Serum 0/33 1/17
Tumoral tissue NA 0/17
Non-tumoral tissue 0/33 0/17
There was no statistically significant difference between groups
(Fisher exact test). NA = not applicable.
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cation results were considered only if the household gene
was also amplified from the same liver fragment.
Group comparison for age showed that HCC occurred
in older cirrhotic patients, as previously reported (35).
HCV genotype 1 was the most frequent in group 1
patients, while non-1 genotypes (mainly genotype 3) were
more frequent in group 2. The association of HCV geno-
types and the development of HCC is controversial. Some
investigators did not find any association between HCC
and HCV genotypes (36) while other reports have associ-
ated genotype 1b with HCC development (37). Despite the
finding of genotype 1b as the most frequent in HCC in
some world regions, some investigators could not estab-
lish a definitive association since this genotype was the
most prevalent in their countries (38). Concerning this
point, it is very interesting that the results in the present
study showed HCV genotype 3 as the more frequent
among HCC cases but this genotype is not the most
frequent in Brazil (29).
An extensive search of the scientific databases re-
vealed that data on the frequency of HCV genotypes in
Brazilian HCC patients have not been published before. To
our knowledge, this is the first study devoted to the deter-
mination of HCV genotypes in Brazilian HCC patients and
our results highlight the need for more studies on the
frequency of HCV genotypes in HCC in Brazil. HCV shows
a high divergence due to the absence of a proofreading
enzyme during its replication and it is possible that HCV
genotype 3 found in Brazil has particular genetic features
that link it to a carcinogenetic pathway. Sequencing of
other genomic regions such as C, NS3 and NS5A, coding
for antigens previously related to HCC development, (39)
will help elucidate this issue.
The two groups were similar regarding biochemical
and coagulation markers and MELD score, since all pa-
tients were cirrhotics waiting for liver transplantation. Se-
rum α-fetoprotein levels were also similar for the two
groups due to the predominance of early and small HCC
(40) as a consequence of the active screening for this
malignant disease in cirrhotic patients by our group. Evalu-
ation of the Child-Turcot Classification modified by Pugh
showed a statistically significant difference due to the
presence of four patients with child A in group 2. Child A
level patients were referred for transplantation due to early
detection of HCC.
In conclusion, a very low occult HBV infection rate
(0.5%) was found in cirrhotic HCV patients with or without
HCC. Only one case with HCC among 17 showed occult
HBV infection detected in serum. These results are prob-
ably related to the low prevalence of HBV infection in our
population. Furthermore, we have also shown that HCV
genotype 3 is frequently found in Brazilian cirrhotic pa-
tients, particularly when they also have HCC. More studies
involving a large number of cases should be carried out to
confirm these data and to further characterize Brazilian
HCV genotype isolates to elucidate genetic features that
might be related to its carcinogenic potential.
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